Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.
- ISLA-101 shows broad antiviral activity against dengue and related viruses
- Phase 2a PROTECT study confirms safety and antiviral signals
- Treatment cohort reveals promising antiviral activity
- Plans underway for Phase 2b and Phase 3 clinical trials
- Regulatory engagement progressing, including with the FDA
Positive Phase 2a Data Highlights ISLA-101’s Potential in Dengue Prevention and Treatment
Island Pharmaceuticals (ASX:ILA) CEO Dr David Foster unveiled new analysis from the Phase 2a PROTECT study of ISLA-101 at the Asia Dengue Summit in Singapore, revealing promising results for the antiviral candidate targeting dengue fever. The study demonstrated that ISLA-101 was safe, achieved desired plasma concentrations, and delivered meaningful reductions in viral load and symptoms in the prophylactic cohort. Early signals of antiviral activity were also observed in the treatment cohort, supporting further clinical development.
Broad Antiviral Profile Backed by Preclinical and Clinical Evidence
ISLA-101 exhibits broad antiviral activity against dengue virus serotypes 1-4, Zika, West Nile, and yellow fever, all flaviviruses transmitted by mosquitoes. Preclinical data showed the drug prevented death in up to 70% of animals exposed to lethal dengue infection and demonstrated protective effects against Zika in animal models. Originally developed as a cancer drug but never approved, ISLA-101’s repurposing taps into a substantial unmet medical need for effective antivirals against mosquito-borne diseases.
Phase 2a PROTECT Study Design and Key Findings
The Phase 2a trial at SUNY Upstate involved a prophylactic cohort dosed with ISLA-101 prior to dengue virus challenge, with a 3:1 active to placebo ratio. The Safety Review Committee confirmed the drug was well tolerated and reached appropriate blood concentrations. The treatment cohort, dosed post-infection, showed evidence of antiviral activity including a negative correlation between the timing of viremia onset and peak viral load, suggesting the drug impacts viral replication dynamics. Full Phase 2b data remains unpublished but a manuscript is in preparation.
Advancing Clinical and Regulatory Pathways with Strategic Partnerships
Buoyed by these results, Island is advancing discussions with potential strategic partners to support additional Phase 2 and Phase 3 trials for both prevention and treatment indications. The company is also engaging with the US FDA to clarify regulatory pathways, including possible Priority Review Voucher eligibility for ISLA-101. Efforts to optimise oral and intravenous formulations are underway to enhance prophylactic and therapeutic use cases.
Dual-Asset Strategy Positions Island for Broader Viral Threat Response
Alongside ISLA-101, Island is progressing Galidesivir, a broad-spectrum antiviral targeting over 20 RNA viruses including Ebola, Marburg, and MERS. Recent developments on Galidesivir’s FDA Animal Rule regulatory pathway and biodefence collaborations complement the company’s focus on urgent viral threats. This dual-program approach underlines Island’s ambition to address significant public health and biosecurity challenges through innovative antiviral therapies.
Bottom Line?
ISLA-101’s Phase 2a success sets the stage for pivotal trials and regulatory milestones that could reshape dengue treatment options.
Questions in the middle?
- How will the forthcoming Phase 2b data shape ISLA-101’s clinical profile and regulatory prospects?
- What timelines and partners will Island Pharmaceuticals secure for Phase 3 dengue trials?
- How might FDA engagement influence the final approval pathway and market access for ISLA-101?